Strategic partnerships Leverage Maxwell's preclinical platform and partnerships with large pharma to pursue co-development, licensing, or milestone-driven deals for CLAROMER™–based candidates targeting SARS-CoV-2, other viruses, and fungal/bacterial pathogens.

Non-dilutive validation Highlight over $35M in government grants and awards as a proof point of scientific merit to potential customers and investors, and use this to de-risk collaborations with big pharma and research institutions.

Targeted collaborations Explore CRADA and CRDA opportunities with government and defense health labs (USAISR, NMRC/NIDDL) to test antiviral and antifungal therapies, creating early-adoption pilots that can scale to broader commercialization.

Expanded IP moat Position the CLAROMER™ platform and stabilized peptide analogs as defensible, patent-protected solutions with multi-asset, multi-target potential to attract licensors and co-development partners seeking novel anti-infective modalities.

Clinical development runway Emphasize preclinical safety data and virucidal activity, plus ongoing spinout activity (SHU.ai) to demonstrate momentum and a diversified portfolio, offering downstream licensing or acquisition scenarios as the platform matures.